The best known predictive biomarkers for the treatment of glioblastoma is MGMT promoter status, in which methylated tumor subtypes have shown greater response to alkylating agents.129, 130 Recently, the antiangiogenic treatment of newly diagnosed glioblastoma was evaluated in 2 phase 3 clinical trials in which bevacizumab, an antibody targeting VEGF, did not result in improved OS when added to the standard treatment.131, 132 Currently, there is no clinically useful molecular marker predictive of treatment response for antiangiogenic therapy. This evidence concerns the gene VEGFA and glioblastoma.